Gabriel Brooks's most recent trade in Solid Biosciences Inc was a trade of 10,937 Common Stock done . Disclosure was reported to the exchange on Feb. 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 10,937 | 95,029 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 10,937 | 21,876 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.44 per share. | 04 Feb 2026 | 12,616 | 84,092 (0%) | 0% | 6.4 | 81,271 | Common Stock |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 207,450 | 207,450 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 103,750 | 103,750 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 58,847 | 0 | - | - | Performance Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 58,847 | 96,818 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.44 per share. | 29 Jan 2026 | 28,335 | 96,708 (0%) | 0% | 6.4 | 182,390 | Common Stock |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 28,225 | 125,043 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 28,225 | 84,675 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2025 | 9,750 | 19,500 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2025 | 9,750 | 36,714 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.96 per share. | 18 Oct 2025 | 2,895 | 33,819 (0%) | 0% | 6.0 | 17,254 | Common Stock |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 142,500 | 142,500 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 71,250 | 71,250 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 10,937 | 32,813 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 10,937 | 26,068 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 3.96 per share. | 13 Feb 2025 | 3,256 | 22,812 (0%) | 0% | 4.0 | 12,894 | Common Stock |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 112,900 | 112,900 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 9,750 | 29,250 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 9,750 | 13,902 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 6.50 per share. | 18 Oct 2024 | 2,923 | 10,979 (0%) | 0% | 6.5 | 19,000 | Common Stock |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 87,500 | 87,500 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Gabriel Brooks | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 43,750 | 43,750 | - | - | Restricted Stock Units |